Caprion Announces Biomarker Discovery Collaboration with Vertex
News Mar 30, 2006
The collaboration will use Caprion's CellCarta® proteomics platform to support clinical biomarker discovery.
Caprion will identify potential pharmacodynamic biomarkers in samples from certain clinical and pre-clinical studies conducted by Vertex.
"Caprion is looking forward to working with Vertex on this clinical biomarker discovery collaboration," noted Dr. Daniel Chelsky, Chief Scientific Officer at Caprion.
"We believe that Caprion's capabilities in the discovery of protein biomarkers may significantly impact development efforts for one or more Vertex compounds."
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE
Eating Activates Calorie-Burning FatNews
The importance of the human brown adipose tissue (BAT) has become clearer during the past ten years. Coldness is one of the most effective activators of the BAT metabolic function but, in rodents, eating has also been shown to activate BAT. The debate on whether eating has the same effect on humans has lasted for decades. Now, the researchers at Turku PET Centre have proven that having a meal increases oxygen consumption in human BAT to the same extent as coldness.READ MORE